Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
According to the latest research, the global Intravenous Immunoglobulin (IVIg) market size was valued at USD 13315.76 million in 2022 and is expected to expand at a CAGR of 10.9% during the forecast period, reaching USD 24771.66 million by 2028.
Intravenous Immunoglobulin (IVIG) is a solution of highly purified Immunoglobulin G, derived from large pools of human plasma that contain antibodies against a broad spectrum of bacterial and viral agents.
Influence of COVID-19 Outbreak on Intravenous Immunoglobulin (IVIg) Industry Development
After the epidemic is over, the people will have higher demand for health management and healthcare, which will promote the growth of medical consumption and open up the market from the demand side.
Immunity is a very important condition when fighting against COVID-19. Through this epidemic, the public's attention to immunity has increased significantly, and the awareness of disease prevention, early medical treatment, treatment methods and drugs, disease prognosis and harm has also been deeper, and the research and development of related drugs and reagents is bound to receive more attention. This will enable the Intravenous Immunoglobulin (IVIg) industry to attract more attention, promote product innovation and development, and stimulate market vitality. It is expected that more pharmaceutical companies will strengthen the R&D and manufacturing of such drugs.
The new crown epidemic has caused the current global plasma collection stations to basically stop the plasma donation. Due to the quarantine period, the stock of plasma must be qualified again after 3 months before it can be put into plasma production. If the epidemic control in European and American countries continues to be unclear, the resumption of pulp mining will become more difficult, which will lead to insufficient supply of pulp. In such a situation where demand exceeds supply, the price of Intravenous Immunoglobulin (IVIg) products will rise rapidly in the short term.
Strength
Rising in the prevalence of immunodeficiency diseases.
Development of cost-Effective therapeutics through large-scale production.
The rapid technological progress of IVIG products.
Huge distribution channels also promote the development of the market.
Weakness
High cost of therapy.
Fierce competition.
Opportunity
Development of the health care infrastructure.
Increasing global population aging.
Developing countries in the Asia-Pacific region, such as China and India, have huge potential markets.
Threat
Stringent government regulations.
Negative effects of the economic downturn.
Tax changes that affect profits or business models.
Region Overview:
North America had the highest growth rate of all regions.
Company Overview:
CSL Behring Biopharmaceuticals Ltd. is one of the major players operating in the Intravenous Immunoglobulin (IVIg) market, holding a share of 16.75% in 2020.
CSL Behring develops, manufactures, and markets protein-based therapies. The Company offers bleeding disorders, fluid replacement, hereditary angioedema, immunoglobulin, pulmonary, and wound healing plasma-derived and recombinant therapies.
Grifols develops, manufactures, and markets plasma derivatives, IV Therapy, enteral nutrition, diagnostic systems, and medical materials.
Segmentation Overview:
Among different product types, IVIg Liquid segment is anticipated to contribute the largest market share in 2027.
Application Overview:
By application, the Autoimmune Disease segment occupied the biggest share from 2017 to 2022.
This report elaborates on the market size, market characteristics, and market growth of the Intravenous Immunoglobulin (IVIg) industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of Intravenous Immunoglobulin (IVIg). The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global Intravenous Immunoglobulin (IVIg) Market Report Include:
Market Size Estimates: Intravenous Immunoglobulin (IVIg) market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: Intravenous Immunoglobulin (IVIg) market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the Intravenous Immunoglobulin (IVIg) market
Segment Market Analysis: Intravenous Immunoglobulin (IVIg) market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: Intravenous Immunoglobulin (IVIg) market situations and prospects in major and top regions and countries
Intravenous Immunoglobulin (IVIg) Market
Intravenous Immunoglobulin (IVIg) Industry Chain: Intravenous Immunoglobulin (IVIg) market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
Intravenous Immunoglobulin (IVIg) Industry News, Policies by regions
Intravenous Immunoglobulin (IVIg) Industry Porters Five Forces Analysis
Key players in the global Intravenous Immunoglobulin (IVIg) market are covered in Chapter 2:
Kedrion Biopharma Inc.
ADMA Biologics, Inc.
China Biologics Products, Inc.
Takeda Pharmaceuticals Hualan Biological Engineering Inc.
LFB group
Octapharma
Shanghai RAAS Blood Products Co. Ltd.
Baxter International Inc.
Grifols
CSL Behring
In Chapter 6 and Chapter 9, on the basis of types, the Intravenous Immunoglobulin (IVIg) market from 2018 to 2028 is primarily split into:
IVIg Liquid
IVIg Powder
In Chapter 7 and Chapter 10, on the basis of applications, the Intravenous Immunoglobulin (IVIg) market from 2018 to 2028 covers:
Immunodeficiency
Autoimmune Disease
Acute Infection
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global Intravenous Immunoglobulin (IVIg) market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the Intravenous Immunoglobulin (IVIg) industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of Intravenous Immunoglobulin (IVIg) market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the Intravenous Immunoglobulin (IVIg) industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on Intravenous Immunoglobulin (IVIg) market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the Intravenous Immunoglobulin (IVIg) market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed Intravenous Immunoglobulin (IVIg) market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
2022
Intravenous Immunoglobulin (IVIG) is a solution of highly purified Immunoglobulin G, derived from large pools of human plasma that contain antibodies against a broad spectrum of bacterial and viral agents.
Influence of COVID-19 Outbreak on Intravenous Immunoglobulin (IVIg) Industry Development
After the epidemic is over, the people will have higher demand for health management and healthcare, which will promote the growth of medical consumption and open up the market from the demand side.
Immunity is a very important condition when fighting against COVID-19. Through this epidemic, the public's attention to immunity has increased significantly, and the awareness of disease prevention, early medical treatment, treatment methods and drugs, disease prognosis and harm has also been deeper, and the research and development of related drugs and reagents is bound to receive more attention. This will enable the Intravenous Immunoglobulin (IVIg) industry to attract more attention, promote product innovation and development, and stimulate market vitality. It is expected that more pharmaceutical companies will strengthen the R&D and manufacturing of such drugs.
The new crown epidemic has caused the current global plasma collection stations to basically stop the plasma donation. Due to the quarantine period, the stock of plasma must be qualified again after 3 months before it can be put into plasma production. If the epidemic control in European and American countries continues to be unclear, the resumption of pulp mining will become more difficult, which will lead to insufficient supply of pulp. In such a situation where demand exceeds supply, the price of Intravenous Immunoglobulin (IVIg) products will rise rapidly in the short term.
Strength
Rising in the prevalence of immunodeficiency diseases.
Development of cost-Effective therapeutics through large-scale production.
The rapid technological progress of IVIG products.
Huge distribution channels also promote the development of the market.
Weakness
High cost of therapy.
Fierce competition.
Opportunity
Development of the health care infrastructure.
Increasing global population aging.
Developing countries in the Asia-Pacific region, such as China and India, have huge potential markets.
Threat
Stringent government regulations.
Negative effects of the economic downturn.
Tax changes that affect profits or business models.
Region Overview:
North America had the highest growth rate of all regions.
Company Overview:
CSL Behring Biopharmaceuticals Ltd. is one of the major players operating in the Intravenous Immunoglobulin (IVIg) market, holding a share of 16.75% in 2020.
CSL Behring develops, manufactures, and markets protein-based therapies. The Company offers bleeding disorders, fluid replacement, hereditary angioedema, immunoglobulin, pulmonary, and wound healing plasma-derived and recombinant therapies.
Grifols develops, manufactures, and markets plasma derivatives, IV Therapy, enteral nutrition, diagnostic systems, and medical materials.
Segmentation Overview:
Among different product types, IVIg Liquid segment is anticipated to contribute the largest market share in 2027.
Application Overview:
By application, the Autoimmune Disease segment occupied the biggest share from 2017 to 2022.
This report elaborates on the market size, market characteristics, and market growth of the Intravenous Immunoglobulin (IVIg) industry between the year 2018 to 2028, and breaks down according to the product type, downstream application, and consumption area of Intravenous Immunoglobulin (IVIg). The report also introduces players in the industry from the perspective of the value chain and looks into the leading companies.
Key Points this Global Intravenous Immunoglobulin (IVIg) Market Report Include:
Market Size Estimates: Intravenous Immunoglobulin (IVIg) market size estimation in terms of revenue and sales from 2018-2028
Market Dynamic and Trends: Intravenous Immunoglobulin (IVIg) market drivers, restraints, opportunities, and challenges
Macro-economy and Regional Conflict: Influence of global inflation and Russia & Ukraine War on the Intravenous Immunoglobulin (IVIg) market
Segment Market Analysis: Intravenous Immunoglobulin (IVIg) market revenue and sales by type and by application from 2018-2028
Regional Market Analysis: Intravenous Immunoglobulin (IVIg) market situations and prospects in major and top regions and countries
Intravenous Immunoglobulin (IVIg) Market
Competitive Landscape
and Major Players: Analysis of 10-15 leading market players, sales, price, revenue, gross, gross margin, product/service profile and recent development/updates, etc.Intravenous Immunoglobulin (IVIg) Industry Chain: Intravenous Immunoglobulin (IVIg) market raw materials & suppliers, manufacturing process, distributors by region, downstream customers
Intravenous Immunoglobulin (IVIg) Industry News, Policies by regions
Intravenous Immunoglobulin (IVIg) Industry Porters Five Forces Analysis
Key players in the global Intravenous Immunoglobulin (IVIg) market are covered in Chapter 2:
Kedrion Biopharma Inc.
ADMA Biologics, Inc.
China Biologics Products, Inc.
Takeda Pharmaceuticals Hualan Biological Engineering Inc.
LFB group
Octapharma
Shanghai RAAS Blood Products Co. Ltd.
Baxter International Inc.
Grifols
CSL Behring
In Chapter 6 and Chapter 9, on the basis of types, the Intravenous Immunoglobulin (IVIg) market from 2018 to 2028 is primarily split into:
IVIg Liquid
IVIg Powder
In Chapter 7 and Chapter 10, on the basis of applications, the Intravenous Immunoglobulin (IVIg) market from 2018 to 2028 covers:
Immunodeficiency
Autoimmune Disease
Acute Infection
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions from 2018 to 2028 are covered in Chapter 8 and Chapter 11:
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
In summary, this report relies on sources from both primary and secondary, combines comprehensive quantitative analysis with detailed qualitative analysis, and pictures the market from a macro overview to micro granular segment aspects. Whatever your role in this industry value chain is, you should benefit from this report with no doubt.
Chapter Outline
This report consists of 12 chapters. Below is a brief guideline to help you quickly grasp the main contents of each chapter:
Chapter 1 first introduces the product overview, market scope, product classification, application, and regional division, and then summarizes the global Intravenous Immunoglobulin (IVIg) market size in terms of revenue, sales volume, and average price.
Chapter 2 analyzes the main companies in the Intravenous Immunoglobulin (IVIg) industry, including their main businesses, products/services, sales, prices, revenue, gross profit margin, and the latest developments/updates.
Chapter 3 is an analysis of the competitive environment of Intravenous Immunoglobulin (IVIg) market participants. This mainly includes the revenue, sales, market share, and average price of the top players, along with the market concentration ratio in 2022 and the players' M&A and expansion in recent years.
Chapter 4 is an analysis of the Intravenous Immunoglobulin (IVIg) industrial chain, including raw material analysis, manufacturing cost structure, distributors, and major downstream buyers.
Chapter 5 focuses on Intravenous Immunoglobulin (IVIg) market dynamics and marketing strategy analysis, which include opportunities, challenges, industry development trends under inflation, industry news and policies analyzed by region, Porter's Five Forces analysis, as well as direct and indirect marketing, and the development trends of marketing channels.
Chapters 6-8 have segmented the Intravenous Immunoglobulin (IVIg) market by type, application, and region, with a focus on sales and value from 2018 to 2023 from both vertical and horizontal perspectives.
Chapters 9-11 provide detailed Intravenous Immunoglobulin (IVIg) market forecast data for 2023-2028, broken down by type and application, region, and major countries to help understand future growth trends.
Chapter 12 concludes with an explanation of the data sources and research methods. Verify and analyze through preliminary research to obtain final quantitative and qualitative data.
Years considered for this report:
Historical Years:
2018-2022Base Year:
2022Estimated Year:
2023Forecast Period:
2023-2028Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
